<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Thyroid Ultrasound Guide - Skolyn Documentation</title>
<link href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700&family=Google+Sans+Text:wght@400;500&display=swap" rel="stylesheet">
<style>*{margin:0;padding:0;box-sizing:border-box}body{font-family:'Google Sans Text','Google Sans',Roboto,'Helvetica Neue',Arial,sans-serif;max-width:900px;margin:0 auto;padding:48px 40px;color:#1d1d1f;line-height:1.8;font-size:15px}.doc-id-bar{display:flex;justify-content:space-between;align-items:center;padding:12px 20px;background:#f8f9fa;border:1px solid #e8eaed;border-radius:8px;margin-bottom:24px;font-size:13px;color:#5f6368}.doc-id-bar .doc-id{font-family:'Google Sans',sans-serif;font-weight:700;color:#1a73e8;font-size:14px;letter-spacing:.5px}.doc-id-bar .doc-class{padding:4px 12px;background:#e8f0fe;color:#1a73e8;border-radius:100px;font-weight:500;font-size:12px}.doc-header{border-bottom:3px solid #00897b;padding-bottom:28px;margin-bottom:40px}.doc-header h1{font-family:'Google Sans',sans-serif;font-size:32px;font-weight:700;margin-bottom:8px}.doc-header .subtitle{font-size:16px;color:#5f6368;margin-bottom:16px}.doc-header .meta-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(200px,1fr));gap:12px;font-size:13px;color:#5f6368}.doc-header .meta-item{display:flex;align-items:center;gap:6px}.doc-header .meta-item strong{color:#1d1d1f}h2{font-family:'Google Sans',sans-serif;font-size:22px;color:#00897b;margin:40px 0 16px;padding-bottom:8px;border-bottom:1px solid #e8eaed}h3{font-family:'Google Sans',sans-serif;font-size:17px;color:#202124;margin:28px 0 12px}p{margin-bottom:14px}ul,ol{margin:0 0 18px 24px}li{margin-bottom:8px}table{width:100%;border-collapse:collapse;margin:16px 0 24px;font-size:13px}th,td{padding:10px 14px;text-align:left;border:1px solid #dadce0}th{background:#e0f2f1;font-weight:600;color:#00695c}td{color:#3c4043}tr:nth-child(even) td{background:#fafafa}code{background:#f1f3f4;padding:2px 8px;border-radius:4px;font-size:13px}.signature-section{margin-top:64px;page-break-inside:avoid}.signature-section .section-title{font-family:'Google Sans',sans-serif;font-size:18px;font-weight:700;color:#1d1d1f;margin-bottom:24px;padding-bottom:12px;border-bottom:2px solid #1d1d1f}.signature-grid{display:grid;grid-template-columns:1fr 1fr;gap:48px}.signature-block{border:1px solid #dadce0;border-radius:12px;padding:32px;background:#fafafa}.signature-block .role{font-family:'Google Sans',sans-serif;font-size:16px;font-weight:700;margin-bottom:4px}.signature-block .name{font-size:14px;color:#5f6368;margin-bottom:24px}.signature-line{border-bottom:1px solid #1d1d1f;height:48px;margin-bottom:8px}.signature-label{font-size:12px;color:#80868b;margin-bottom:16px}.stamp-area{border:2px dashed #dadce0;border-radius:8px;height:100px;display:flex;align-items:center;justify-content:center;color:#80868b;font-size:12px;margin-top:16px}.doc-footer{margin-top:48px;padding-top:24px;border-top:2px solid #e8eaed;font-size:12px;color:#5f6368;text-align:center}.doc-footer p{margin-bottom:4px}@media print{body{max-width:100%;padding:20px;font-size:12px}.signature-section{page-break-before:always}}</style>
</head>
<body>

<div class="doc-id-bar"><span class="doc-id">SKL-US-004</span><span>Skolyn Platform Documentation</span><span class="doc-class">CONFIDENTIAL</span></div>

<div class="doc-header">
  <h1>Thyroid Ultrasound Guide</h1>
  <div class="subtitle">AI-Powered Thyroid Nodule Assessment: TI-RADS Classification, Risk Stratification, and Follow-Up Management</div>
  <div class="meta-grid">
    <div class="meta-item"><strong>Version:</strong> 3.0</div>
    <div class="meta-item"><strong>Last Updated:</strong> February 2026</div>
    <div class="meta-item"><strong>Classification:</strong> Confidential</div>
    <div class="meta-item"><strong>Owner:</strong> Ultrasound Engineering</div>
  </div>
</div>

<h2>1. Overview</h2>
<p>Thyroid nodules are extraordinarily common, detected in up to 68% of the adult population by high-resolution ultrasound. The clinical challenge is identifying the small minority (5-15%) that harbor malignancy among the vast majority of benign nodules, avoiding unnecessary biopsies while not missing cancers. Skolyn's thyroid ultrasound AI within Scandium OS implements the ACR Thyroid Imaging, Reporting and Data System (TI-RADS) to provide standardized, reproducible nodule characterization and risk assessment. The module automates nodule detection, multi-feature sonographic characterization, TI-RADS point scoring and category assignment, size-based biopsy recommendation, and longitudinal growth tracking. By providing consistent, guideline-compliant assessment, the AI reduces unnecessary FNA biopsies by an estimated 30% while maintaining 97% sensitivity for clinically significant thyroid cancers.</p>

<h2>2. Nodule Detection and Measurement</h2>
<p>The detection engine identifies all discrete thyroid nodules using a YOLO-v8 object detection model trained on 50,000 annotated thyroid ultrasound images. Each detected nodule is automatically measured in three dimensions (AP, transverse, and longitudinal) with volume calculated using the ellipsoid formula (length x width x height x 0.524). The largest dimension is used for TI-RADS size-based biopsy threshold determination. Nodule location is recorded by thyroid lobe (right, left, isthmus) and position within the lobe (upper pole, mid, lower pole). For multi-nodular thyroid glands, each nodule is assigned a unique identifier for individual assessment and tracking. Total thyroid gland volume is also calculated for assessment of thyromegaly.</p>

<h2>3. TI-RADS Feature Assessment</h2>
<h3>3.1 Five Feature Categories</h3>
<p>Each nodule is evaluated across five sonographic feature categories per ACR TI-RADS, with points assigned based on suspicious morphology. Composition (0-2 points): cystic or predominantly cystic (0), spongiform (0), mixed solid and cystic (1), solid or predominantly solid (2). Echogenicity (0-3 points): anechoic (0), hyperechoic or isoechoic (1), hypoechoic (2), very hypoechoic (3). Shape (0-3 points): wider-than-tall (0), taller-than-wide (3). Margin (0-3 points): smooth (0), ill-defined (0), lobulated or irregular (2), extrathyroidal extension (3). Echogenic foci (0-3 points): none or large comet-tail artifacts (0), macrocalcification (1), peripheral/rim calcification (2), punctate echogenic foci (3).</p>

<h3>3.2 Category Assignment</h3>
<table>
  <tr><th>TI-RADS Category</th><th>Points</th><th>Risk Level</th><th>Associated Malignancy Rate</th></tr>
  <tr><td>TR1 (Benign)</td><td>0</td><td>Benign</td><td>&lt;2%</td></tr>
  <tr><td>TR2 (Not Suspicious)</td><td>2</td><td>Very Low</td><td>&lt;5%</td></tr>
  <tr><td>TR3 (Mildly Suspicious)</td><td>3</td><td>Low</td><td>5-10%</td></tr>
  <tr><td>TR4 (Moderately Suspicious)</td><td>4-6</td><td>Moderate</td><td>10-50%</td></tr>
  <tr><td>TR5 (Highly Suspicious)</td><td>&ge;7</td><td>High</td><td>&gt;50%</td></tr>
</table>

<h2>4. Biopsy Recommendations</h2>
<p>Following ACR TI-RADS guidelines, biopsy recommendations are determined by both the TI-RADS category and nodule size. TR1 — no FNA needed regardless of size. TR2 — no FNA needed regardless of size. TR3 — FNA if &ge;2.5cm, follow-up if &ge;1.5cm. TR4 — FNA if &ge;1.5cm, follow-up if &ge;1.0cm. TR5 — FNA if &ge;1.0cm, follow-up if &ge;0.5cm. The system also considers additional factors that may modify the recommendation, including patient age, family history of thyroid cancer, prior radiation exposure, and suspicious cervical lymphadenopathy. When cervical lymph nodes are abnormal (rounded morphology, microcalcification, cystic change, loss of normal hilum), the system recommends concurrent lymph node FNA.</p>

<h2>5. Longitudinal Tracking</h2>
<p>For nodules under surveillance, the system performs automated comparison with prior studies using registration-based nodule matching. Growth is assessed by volume change (significant growth defined as &ge;50% volume increase or &ge;2mm increase in at least two dimensions, per ACR criteria). Growth rate analysis distinguishes benign patterns (slow, linear growth) from suspicious patterns (rapid doubling time, interval morphological change). The system generates structured follow-up recommendations based on TI-RADS category: TR3 — follow-up at 1, 3, and 5 years; TR4 — follow-up at 1, 2, 3, and 5 years; TR5 — follow-up annually for 5 years. Stable nodules with no growth over 5 years can be discharged from surveillance.</p>

<h2>6. Clinical Performance</h2>
<table>
  <tr><th>Task</th><th>Metric</th><th>Performance</th><th>Benchmark</th></tr>
  <tr><td>Nodule Detection</td><td>Sensitivity</td><td>95.7%</td><td>6K clinical studies</td></tr>
  <tr><td>TI-RADS Category</td><td>Agreement (kappa)</td><td>0.84</td><td>Expert consensus</td></tr>
  <tr><td>Feature Classification</td><td>Accuracy</td><td>91.3%</td><td>Expert annotation</td></tr>
  <tr><td>Malignancy Prediction</td><td>AUC</td><td>0.938</td><td>Pathology-confirmed</td></tr>
  <tr><td>Biopsy Recommendation</td><td>Guideline Compliance</td><td>97.8%</td><td>ACR TI-RADS guidelines</td></tr>
</table>

<h2>7. Document Revision History</h2>
<table>
  <tr><th>Version</th><th>Date</th><th>Author</th><th>Changes</th></tr>
  <tr><td>1.0</td><td>2024-06-15</td><td>Ultrasound Engineering</td><td>Initial release</td></tr>
  <tr><td>2.0</td><td>2025-06-01</td><td>Ultrasound Engineering</td><td>Added ACR TI-RADS v2, tracking</td></tr>
  <tr><td>3.0</td><td>2026-02-10</td><td>Ultrasound Engineering</td><td>Updated performance, lymph node assessment</td></tr>
</table>

<div class="signature-section">
  <div class="section-title">Authorization & Approval</div>
  <p style="font-size:13px;color:#5f6368;margin-bottom:24px;">This document has been reviewed and approved by the undersigned officers of Skolyn.</p>
  <div class="signature-grid">
    <div class="signature-block"><div class="role">Chief Technology Officer (CTO)</div><div class="name">Skolyn Technology Division</div><div class="signature-line"></div><div class="signature-label">Signature</div><div style="display:flex;justify-content:space-between;margin-bottom:16px"><div><span class="signature-label">Printed Name:</span> ___________________________</div></div><div><span class="signature-label">Date:</span> ______ / ______ / ____________</div><div class="stamp-area">Official Stamp / Seal</div></div>
    <div class="signature-block"><div class="role">Chief Executive Officer (CEO)</div><div class="name">Skolyn Executive Office</div><div class="signature-line"></div><div class="signature-label">Signature</div><div style="display:flex;justify-content:space-between;margin-bottom:16px"><div><span class="signature-label">Printed Name:</span> ___________________________</div></div><div><span class="signature-label">Date:</span> ______ / ______ / ____________</div><div class="stamp-area">Official Stamp / Seal</div></div>
  </div>
</div>

<div class="doc-footer"><p><strong>Skolyn</strong> — Redefining Medical Imaging Through Explainable AI</p><p>Document ID: SKL-US-004 | Version 3.0 | Classification: Confidential</p><p>&copy; 2026 Skolyn. All rights reserved.</p></div>

</body>
</html>
